The global CAR-T cell therapy market size was estimated to be USD 3.39 billion in 2023 and is expected to reach at USD 34.04 billion by 2034 with a CAGR of 23.33% during the forecast period 2024-2034. Increasing chronic diseases such as cancer & leukemia prevalence, increased focus on cell therapy development, increased investment in new CAR T-cell therapy development, rising R&D activities, rapid technological advancements, growing number of new drug product launches, and rising regulatory approval of novel CAR-T cell therapies are some of the major factors driving the market growth.
Rising regulatory approval of novel CAR-T cell therapies is predicted to boost the market growth during the forecast period. A revolutionary method in the treatment of cancer is CAR T-cell therapy. By utilizing the patient's own immune system, this novel immunotherapy fights cancer effectively. It has been demonstrated that CAR T-cell therapy can be a revolutionary therapeutic option for patients who have not responded to traditional therapies. It has demonstrated extraordinary effectiveness in treating some types of hematologic malignancies, such as certain forms of leukemia and lymphoma. CAR T cell treatments have therefore emerged as a viable alternative in the ongoing projects underway to produce more focused disease therapeutics. For instance, in August 2023, NXC-201 (Nexcella), a next-generation chimeric antigen receptor (CAR) T-cell therapy, was given orphan drug designation (ODD) by the US FDA to treat patients with multiple myeloma.
By drug type, Yescarta was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the rise in prevalence of B-cell lymphoma and surge in number of adult patients with large B-cell lymphomas that do not respond to first-line chemotherapy or that relapse within a year after starting first-line chemotherapy are being treated with axicabtagene ciloleucel. Additionally, Carvykti is predicted to grow at the fastest CAGR during the forecast period owing to an increase in clinical trial processes and a rise in regulatory approvals. For instance, in February 2022, A BCMA-directed CAR-T immunotherapy called CARVYKTI (ciltacabtagene autoleucel) has been authorized by the US Food and Drug Administration for the treatment of patients with relapsed or refractory multiple myeloma, according to a statement made by Johnson & Johnson Services, Inc., one of the biggest healthcare companies.
By application, multiple myeloma was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the growing number of FDA approvals, rising incidence of multiple myeloma, and a rise in strategic activities including partnerships and collaborations by industry participants. For instance, in October 2022, The FDA has given accelerated approval to Tecvayli (teclistamab-cqyv), developed by Janssen Biotech, Inc. It is the initial bispecific CD3 T-cell engager targeting B-cell maturation antigen (BCMA). This approval is only valid for adult patients with relapsed or resistant multiple myeloma who have received therapy with at least four distinct therapies in the past, such as immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Additionally, lymphoma is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of lymphoma and a rise in studies and efforts to develop CAR T-cell treatment for the disease.
By end-user, hospitals was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the large number of patients receiving cancer treatment in hospitals, increasing use of cutting-edge technology, and well-equipped operating rooms offered by hospitals. Additionally, cancer treatment centers is predicted to grow at the fastest CAGR during the forecast period owing to the availability of a broad range of therapeutic options, an increase in cancer facilities, and the growing number of clinical trial methods. For instance, in May 2023, Autolus Therapeutics plc has revealed that the abstract from the crucial Phase 2 FELIX trial of obecabtagene autoleucel (obe-cel) for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been chosen for an oral presentation at the European Hematology Association (EHA) 2023 Congress.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of chronic conditions including cancer and autoimmune diseases, increasing demand for innovative CAR T-cell therapy, clinical trials demonstrating promising outcomes in CAR T-cell therapies, and an increase in regulatory body approvals. For instance, in August 2023, According to Invectys, IVS-3001, a chimeric antigen receptor (CAR) T-cell therapy intended to treat patients with renal cell carcinoma, has been given Fast Track Designation by the FDA. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the expanding efforts to study and develop new CAR T-cell treatments, the existence of large market participants, and the rapid increase in new medication approvals by regulatory bodies. For instance, in December 2023, Bristol-Myers Squibb disclosed the approval of the supplemental New Drug Application for an expanded indication of Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T cell immunotherapy targeting B-cell maturation antigen (BCMA). The approval is for patients with relapsed or refractory multiple myeloma (RRMM) who have undergone a minimum of two prior treatments, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Rising regulatory approval of novel CAR-T cell therapies is predicted to boost the market growth during the forecast period. A revolutionary method in the treatment of cancer is CAR T-cell therapy. By utilizing the patient's own immune system, this novel immunotherapy fights cancer effectively. It has been demonstrated that CAR T-cell therapy can be a revolutionary therapeutic option for patients who have not responded to traditional therapies. It has demonstrated extraordinary effectiveness in treating some types of hematologic malignancies, such as certain forms of leukemia and lymphoma. CAR T cell treatments have therefore emerged as a viable alternative in the ongoing projects underway to produce more focused disease therapeutics. For instance, in August 2023, NXC-201 (Nexcella), a next-generation chimeric antigen receptor (CAR) T-cell therapy, was given orphan drug designation (ODD) by the US FDA to treat patients with multiple myeloma.
By drug type, Yescarta was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the rise in prevalence of B-cell lymphoma and surge in number of adult patients with large B-cell lymphomas that do not respond to first-line chemotherapy or that relapse within a year after starting first-line chemotherapy are being treated with axicabtagene ciloleucel. Additionally, Carvykti is predicted to grow at the fastest CAGR during the forecast period owing to an increase in clinical trial processes and a rise in regulatory approvals. For instance, in February 2022, A BCMA-directed CAR-T immunotherapy called CARVYKTI (ciltacabtagene autoleucel) has been authorized by the US Food and Drug Administration for the treatment of patients with relapsed or refractory multiple myeloma, according to a statement made by Johnson & Johnson Services, Inc., one of the biggest healthcare companies.
By application, multiple myeloma was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the growing number of FDA approvals, rising incidence of multiple myeloma, and a rise in strategic activities including partnerships and collaborations by industry participants. For instance, in October 2022, The FDA has given accelerated approval to Tecvayli (teclistamab-cqyv), developed by Janssen Biotech, Inc. It is the initial bispecific CD3 T-cell engager targeting B-cell maturation antigen (BCMA). This approval is only valid for adult patients with relapsed or resistant multiple myeloma who have received therapy with at least four distinct therapies in the past, such as immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Additionally, lymphoma is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of lymphoma and a rise in studies and efforts to develop CAR T-cell treatment for the disease.
By end-user, hospitals was the highest revenue-grossing segment in the global CAR-T cell therapy market in 2023 owing to the large number of patients receiving cancer treatment in hospitals, increasing use of cutting-edge technology, and well-equipped operating rooms offered by hospitals. Additionally, cancer treatment centers is predicted to grow at the fastest CAGR during the forecast period owing to the availability of a broad range of therapeutic options, an increase in cancer facilities, and the growing number of clinical trial methods. For instance, in May 2023, Autolus Therapeutics plc has revealed that the abstract from the crucial Phase 2 FELIX trial of obecabtagene autoleucel (obe-cel) for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) has been chosen for an oral presentation at the European Hematology Association (EHA) 2023 Congress.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of chronic conditions including cancer and autoimmune diseases, increasing demand for innovative CAR T-cell therapy, clinical trials demonstrating promising outcomes in CAR T-cell therapies, and an increase in regulatory body approvals. For instance, in August 2023, According to Invectys, IVS-3001, a chimeric antigen receptor (CAR) T-cell therapy intended to treat patients with renal cell carcinoma, has been given Fast Track Designation by the FDA. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the expanding efforts to study and develop new CAR T-cell treatments, the existence of large market participants, and the rapid increase in new medication approvals by regulatory bodies. For instance, in December 2023, Bristol-Myers Squibb disclosed the approval of the supplemental New Drug Application for an expanded indication of Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T cell immunotherapy targeting B-cell maturation antigen (BCMA). The approval is for patients with relapsed or refractory multiple myeloma (RRMM) who have undergone a minimum of two prior treatments, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: CAR-T Cell Therapy Market Report 2023 - 2034
CAR-T Cell Therapy Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Abecma
- Yescarta
- Kymriah
- Breyanzi
- Tecartus
- Others
CAR-T Cell Therapy Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Autoimmune Disorders
- Multiple Myeloma
- Lymphoma
- Leukaemia
- Others
CAR-T Cell Therapy Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Cancer Treatment Centers
- Others
CAR-T Cell Therapy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. CAR-T Cell Therapy Market: Drug Type Estimates & Trend Analysis
8. CAR-T Cell Therapy Market: Application Estimates & Trend Analysis
9. CAR-T Cell Therapy Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America CAR-T Cell Therapy Market
12. Europe CAR-T Cell Therapy Market
13. Asia Pacific CAR-T Cell Therapy Market
14. Latin America CAR-T Cell Therapy Market
15. MEA CAR-T Cell Therapy Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Celyad Oncology
- Sangamo Therapeutics Inc.
- Novartis AG
- ACROBiosystems
- Miltenyi Biotec
- Johnson & Johnson
- Servier Laboratories
- Gilead Sciences Inc. (Kite Pharma)
- Sorrento Therapeutics Inc.
- Noile-Immune Biotech Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.39 Billion |
| Forecasted Market Value ( USD | $ 34.04 Billion |
| Compound Annual Growth Rate | 23.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
